Blog
RSS FeedPosted by Michael Wonder on 23 Jun 2026
Allergan Aesthetics receives approval for Boey (trenibotulinumtoxinE) in Canada, the first and only rapid-onset, short-duration neurotoxin for the temporary improvement of frown lines in adult patients
23 June 2026 - Today, Allergan Aesthetics announced Health Canada has approved Boey (trenibotulinumtoxinE) for the temporary improvement in the ...
Posted by Michael Wonder on 17 Jun 2026
Health Canada approves Zepbound as the first ever obstructive sleep apnea medication in Canada for adults living with obesity
16 June 2026 - Eli Lilly Canada announced today that Health Canada has approved Zepbound (tirzepatide injection) for the treatment of ...
Posted by Michael Wonder on 17 Jun 2026
Exdensur (depemokimab injection) approved in Canada for the treatment of severe asthma and chronic rhinosinusitis with nasal polyps
16 June 2026 - GSK announced today that Health Canada has approved Exdensur (depemokimab) for two indications. ...
Posted by Michael Wonder on 11 Jun 2026
Italfarmaco announces Health Canada acceptance and priority review of new drug submission for givinostat as a Duchenne muscular dystrophy treatment
10 June 2026 - New drug submission is based on Italfarmaco’s Phase 3 EPIDYS trial data demonstrating meaningful treatment benefits ...
Posted by Michael Wonder on 11 Jun 2026
Zemcelpro (UM171 cell therapy) licensing and supply agreements announced for Canada
10 June 2026 - ExCellThera today announced exclusive licensing and supply agreements granting Medexus the Canadian commercialization rights for Zemcelpro ...
Posted by Michael Wonder on 10 Jun 2026
Chiesi Global Rare Diseases announces Health Canada grants priority review for Filsuvez (birch triterpenes) topical gel for the treatment of epidermolysis bullosa
9 June 2026 - Chiesi Global Rare Diseases today announced that Health Canada has accepted the new drug submission for Filzuvez ...
Posted by Michael Wonder on 10 Jun 2026
Nucala (mepolizumab) approved in Canada for use in adults with chronic obstructive pulmonary disease
9 June 2026 - GSK announced today that Health Canada has approved Nucala (mepolizumab) as an add-on maintenance treatment in ...
Posted by Michael Wonder on 09 Jun 2026
Health Canada authorizes Lunsumio (mosunetuzumab) for the treatment of relapsed or refractory follicular lymphoma after two or more systemic therapies
8 June 2026 - Roche Canada is pleased to announce that Health Canada has granted market authorisations for Lunsumio (mosunetuzumab ...
Posted by Michael Wonder on 05 Jun 2026
Kashiv BioSciences announces validation and acceptance of market authorisation application by Health Canada for ADL-018, a proposed biosimilar to Xolair (omalizumab)
4 June 2026 - Kashiv BioSciences today announced that Health Canada has validated and accepted the marketing authorisation application for ADL-018, ...
Posted by Michael Wonder on 04 Jun 2026
Why Canada has generic Ozempic, and the US doesn't
3 June 2026 - Elizabeth Doran has been taking GLP-1 medications for nearly a year for weight loss to help ...
Posted by Michael Wonder on 03 Jun 2026
Celltrion files for approval of Cosentyx biosimilar, CT-P55, in Canada
1 June 2026 - Celltrion announced on Monday that it has submitted a regulatory application to Health Canada for CT-P55, ...
Posted by Michael Wonder on 02 Jun 2026
Loargys (pegzilarginase for injection) approved in Canada for the treatment of arginase 1 deficiency
1 June 2026 - Immedica announces that Health Canada has granted a Notice of Compliance on 29 May 2026 for Loargys ...
Posted by Michael Wonder on 27 May 2026
Apotex expands ophthalmic portfolio with Health Canada approval of Iheezo
26 May 2026 - Apotex today announced that Health Canada has approved Iheezo (chloroprocaine hydrochloride ophthalmic gel 3%), a topical ...
Posted by Michael Wonder on 20 May 2026
BioSyent announces Health Canada approval of Thyconvi (levothyroxine oral solution)
19 May 2026 - BioSyent announces that Health Canada has approved Thyconvi (levothyroxine sodium), the first and only levothyroxine oral ...
Posted by Michael Wonder on 15 May 2026
Apotex launches Apo‑Semaglutide Injection, a generic equivalent of Ozempic, in Canada
14 May 2026 - Apotex today announced the commercial launch of Apo‑Semaglutide Injection – a generic equivalent of Ozempic. ...